A detailed history of Tema Etfs LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Tema Etfs LLC holds 30,293 shares of RCUS stock, worth $607,980. This represents 0.03% of its overall portfolio holdings.

Number of Shares
30,293
Previous 59,662 49.23%
Holding current value
$607,980
Previous $486 Million 15.17%
% of portfolio
0.03%
Previous 0.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 24, 2025

SELL
$8.22 - $13.6 $241,413 - $399,418
-29,369 Reduced 49.23%
30,293 $412 Million
Q2 2025

Aug 13, 2025

BUY
$6.87 - $10.03 $305,103 - $445,442
44,411 Added 291.2%
59,662 $486 Million
Q1 2025

May 14, 2025

SELL
$7.85 - $15.24 $54,808 - $106,405
-6,982 Reduced 31.4%
15,251 $120 Million
Q4 2024

Feb 14, 2025

BUY
$14.28 - $18.44 $317,487 - $409,976
22,233 New
22,233 $331 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.45B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Tema Etfs LLC Portfolio

Follow Tema Etfs LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tema Etfs LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tema Etfs LLC with notifications on news.